MetLife Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

MetLife Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.24M	Buy	130,171 +12,318	+10%	+$95.7K	0.01%	1299
2025 Q4	$919K	Sell	117,853 -102	-0.1%	-$737	﹤0.01%	1479
2025 Q3	$895K	Sell	117,955 -6,322	-5%	-$52.6K	﹤0.01%	1507
2025 Q2	$1.11M	Buy	124,277 +2,359	+2%	+$22K	0.01%	1248
2025 Q1	$914K	Sell	121,918 -5,031	-4%	-$40.6K	﹤0.01%	1418
2024 Q4	$955K	Buy	126,949 +7,199	+6%	+$54.6K	0.01%	1444
2024 Q3	$910K	Hold	119,750	–	–	0.01%	1444
2024 Q2	$740K	Buy	119,750 +30,780	+35%	+$170K	﹤0.01%	1510
2024 Q1	$452K	Sell	88,970 -8,391	-9%	-$47.2K	﹤0.01%	1734
2023 Q4	$583K	Hold	97,361	–	–	﹤0.01%	1598
2023 Q3	$689K	Hold	97,361	–	–	0.01%	1440
2023 Q2	$685K	Hold	97,361	–	–	0.01%	1489
2023 Q1	$812K	Hold	97,361	–	–	0.01%	1341
2022 Q4	$1.12M	Hold	97,361	–	–	0.01%	1169
2022 Q3	$1.23M	Hold	97,361	–	–	0.01%	1089
2022 Q2	$1.03M	Hold	97,361	–	–	0.01%	1193
2022 Q1	$1.58M	Buy	97,361 +35,347	+57%	+$567K	0.01%	1087
2021 Q4	$859K	Hold	62,014	–	–	0.01%	1194
2021 Q3	$891K	Sell	62,014 -6,166	-9%	-$97.2K	0.01%	1179
2021 Q2	$1.08M	Hold	68,180	–	–	0.01%	1123
2021 Q1	$693K	Sell	68,180 -4,670	-6%	-$48.2K	0.01%	1336
2020 Q4	$543K	Buy	72,850 +2,769	+4%	+$14.3K	0.01%	1452
2020 Q3	$241K	Hold	70,081	–	–	﹤0.01%	1753
2020 Q2	$334K	Buy	70,081 +30,992	+79%	+$124K	﹤0.01%	1602
2020 Q1	$78.2K	Sell	39,089 -31,360	-45%	-$86.3K	﹤0.01%	2186
2019 Q4	$243K	Buy	70,449 +19,861	+39%	+$50K	﹤0.01%	1879
2019 Q3	$145K	Hold	50,588	–	–	﹤0.01%	2124
2019 Q2	$192K	Hold	50,588	–	–	﹤0.01%	2050
2019 Q1	$412K	Hold	50,588	–	–	﹤0.01%	1577
2018 Q4	$408K	Hold	50,588	–	–	0.01%	1493
2018 Q3	$386K	Buy	50,588 +7,707	+18%	+$51.8K	﹤0.01%	1698
2018 Q2	$246K	Hold	42,881	–	–	﹤0.01%	1822
2018 Q1	$205K	Hold	42,881	–	–	﹤0.01%	1875
2017 Q4	$211K	Buy	+42,881	New	+$208K	﹤0.01%	1904

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

MetLife Investment Management's BCRX Position: Q1 2026 in Review

MetLife Investment Management increased its BioCryst Pharmaceuticals (BCRX) stake by 10% in Q1 2026, buying an estimated $95.7K and bringing the position to 130,171 shares worth $1.24M. The position accounts for 0.01% of the portfolio, ranked #1299.

MetLife Investment Management first reported a position in BCRX in Q4 2017 and has held it in 34 quarters since. The position peaked at $1.58M in Q1 2022. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

MetLife Investment Management held 130,171 shares of BioCryst Pharmaceuticals worth $1.24M as of Q1 2026.
MetLife Investment Management bought 12,318 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $95.7K.
BioCryst Pharmaceuticals made up 0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1299 holding.
MetLife Investment Management first reported a position in BioCryst Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
MetLife Investment Management's BioCryst Pharmaceuticals position peaked at $1.58M in Q1 2022.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.